Boulevard Bio

boulevardbio.com

boulevardbio.com • 201-500 employees

201-500 employees

Actively hiring

Immunology & Inflammation Therapeutics

As featured in

Yahoo Finance

Bioworld

Morningstar

Overview

News

Salaries

Products

People

Growth

Offices

Financials

Overview

Boulevard Bio develops multi-specific antibodies for B cell-driven autoimmune diseases through precision immunology.

News

News YahooFinance 2 months ago

AlivaMab Biologics and Ablexis Congratulate Boulevard Bio on its Launch and the Ongoing Phase 1 Clinical Trial of Bispecific Antibody BLVD101

Fully human dual-antagonist bispecific antibody discovered and engineered at AlivaMab Biologics SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / AlivaMab Biologics, LLC ("AMB"), a leader in the discovery and engineering of superior biologic drugs, ...

Report

News bioworld.com 2 months ago

Boulevard Bio launches with focus on autoimmune diseases Read more

Report

News YahooFinance 2 months ago

Boulevard Bio Launches with $65 Million from Deerfield and World-Class Founders to Advance Precision Immunology Pipeline

Boulevard Bio today announced its emergence from stealth with $65 million from founding investor Deerfield Management and early Phase 1 healthy volunteer data for lead candidate BLVD101, a dual BAFF/APRIL-targeting bispecific antibody, supporting a 12-wee

Report

Press release morningstar.com 4 months ago

METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager Read more

Report

Blog 5 months ago

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing! The post Hello world! appeared first on Boulevard Bio.

Report